projects in our pipeline 21 new molecular entities in our late-stage pipeline 3 new molecular entities under review Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in ...
AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading and diverse pipeline in haematology at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition 7 to 10 December 2024. A total of 57 abstracts w...
We expect another year of strong growth in 2024, driven by continued adoption of our medicines across geographies. Our differentiated and growing portfolio of approved medicines, global reach and rich R&D pipeline give us confidence that we will continue to deliver industry-leading growth." Key mile...
projects in our pipeline View pipeline Learn about our cell therapy ambition The Discovery Centre in Cambridge (UK) is one of our global science centres Explore all our science centres Sustainability at AstraZeneca Corporate Press Release Lynparza demonstrated clinically meaningful prolonged survival bene...
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolioMay 1, 2024 | 37 min read Twitter LinkedIn Facebook Email Print AstraZ...
7 October 2024 AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy AstraZeneca has entered into an exclusive license agreement with CSPC PharmaceuticalGroupLtd(CSPC) to advance the development of an early stage, novel small molecule Lipoprotein...
AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading portfolio and pipeline at the American Society of Clinical Oncology Annual Meeting, May 31 to June 4, 2024.
AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024 7 November 2024 AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA ...
AstraZeneca's drug pipeline has evolved significantly under CEO Pascal Soriot since he took over more than a decade ago, and new technologies such as antibody-drug conjugates are making up a rising proportion of its portfolio of future cancer therapies....
AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024 7 November 2024 AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA ...